Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
暂无分享,去创建一个
A. Russo | F. Fulfaro | N. Gebbia | V. Bazan | G. Bronte | S. Rizzo | D. Fanale | D. Santini | N. Silvestris | G. Gulotta | L. Corsini